China Regenerative Medicine International Management
Management criteria checks 3/4
China Regenerative Medicine International's CEO is Chuang Wang, appointed in Jul 2020, has a tenure of 4.5 years. total yearly compensation is HK$1.46M, comprised of 85.3% salary and 14.7% bonuses, including company stock and options. directly owns 24.28% of the company’s shares, worth HK$22.16M. The average tenure of the management team and the board of directors is 4.5 years and 4 years respectively.
Key information
Chuang Wang
Chief executive officer
HK$1.5m
Total compensation
| CEO salary percentage | 85.3% |
| CEO tenure | 4.5yrs |
| CEO ownership | 24.3% |
| Management average tenure | 4.5yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Little Excitement Around China Regenerative Medicine International Limited's (HKG:8158) Revenues As Shares Take 32% Pounding
Mar 05
China Regenerative Medicine International Limited's (HKG:8158) Price Is Right But Growth Is Lacking After Shares Rocket 57%
Jan 04These 4 Measures Indicate That China Regenerative Medicine International (HKG:8158) Is Using Debt Extensively
Sep 21China Regenerative Medicine International Limited (HKG:8158) May Have Run Too Fast Too Soon With Recent 31% Price Plummet
Jun 11Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
May 22Is China Regenerative Medicine International (HKG:8158) A Risky Investment?
Apr 13Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Sep 22Introducing China Regenerative Medicine International (HKG:8158), The Stock That Zoomed 142% In The Last Year
Mar 16What Is The Ownership Structure Like For China Regenerative Medicine International Limited (HKG:8158)?
Feb 08Trade Alert: The CEO & Executive Chairman Of China Regenerative Medicine International Limited (HKG:8158), Chuang Wang, Has Just Spent HK$55m Buying 428% More Shares
Dec 15
Don't Ignore The Fact That This Insider Just Sold Some Shares In China Regenerative Medicine International Limited (HKG:8158)
Nov 25Does China Regenerative Medicine International (HKG:8158) Have A Healthy Balance Sheet?
Nov 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -HK$104m |
| Mar 31 2024 | n/a | n/a | -HK$101m |
| Dec 31 2023 | HK$1m | HK$1m | -HK$108m |
| Sep 30 2023 | n/a | n/a | HK$677k |
| Jun 30 2023 | n/a | n/a | HK$15m |
| Mar 31 2023 | n/a | n/a | HK$5m |
| Dec 31 2022 | HK$1m | n/a | HK$5m |
| Sep 30 2022 | n/a | n/a | HK$31m |
| Jun 30 2022 | n/a | n/a | HK$26m |
| Mar 31 2022 | n/a | n/a | HK$49m |
| Dec 31 2021 | HK$1m | n/a | HK$52m |
| Sep 30 2021 | n/a | n/a | -HK$95m |
| Jun 30 2021 | n/a | n/a | -HK$82m |
| Mar 31 2021 | n/a | n/a | -HK$105m |
| Dec 31 2020 | HK$1m | n/a | -HK$120m |
| Sep 30 2020 | n/a | n/a | -HK$201m |
| Jun 30 2020 | n/a | n/a | -HK$237m |
| Mar 31 2020 | n/a | n/a | -HK$239m |
| Dec 31 2019 | HK$245k | HK$245k | -HK$264m |
Compensation vs Market: Chuang's total compensation ($USD187.80K) is about average for companies of similar size in the Hong Kong market ($USD231.53K).
Compensation vs Earnings: Chuang's compensation has increased whilst the company is unprofitable.
CEO
Chuang Wang (45 yo)
4.5yrs
Tenure
HK$1,461,000
Compensation
Mr. Chuang Wang has been Executive Chairman at China Regenerative Medicine International Limited since October 18, 2019 and serves as its Chief Executive Officer since July 9, 2020 and also serves as its C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Executive Chairman & Compliance Officer | 4.5yrs | HK$1.46m | 24.28% HK$ 22.2m | |
| CFO & Company Secretary | 2.3yrs | no data | no data | |
| Chief Technology Officer | 6.3yrs | no data | no data |
4.5yrs
Average Tenure
45yo
Average Age
Experienced Management: 8158's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Executive Chairman & Compliance Officer | 5.3yrs | HK$1.46m | 24.28% HK$ 22.2m | |
| Independent Non-Executive Director | 3.1yrs | HK$120.00k | no data | |
| Independent Non-Executive Director | 5yrs | HK$120.00k | no data | |
| Independent Non-Executive Director | 3.1yrs | HK$120.00k | no data |
4.0yrs
Average Tenure
58yo
Average Age
Experienced Board: 8158's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 01:02 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Regenerative Medicine International Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|